Shanghai Haohai Biological Technology Co. Ltd Total Assets
Shanghai Haohai Biological Technology Co. Ltd total assets. Based on the latest financial reports, Shanghai Haohai Biological Technology Co. Ltd (5HB) holds total assets worth €6.72 Billion EUR (≈ $7.86 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Shanghai Haohai Biological Technology Co market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Shanghai Haohai Biological Technology Co. Ltd (2016–2025)
Total assets of Shanghai Haohai Biological Technology Co. Ltd from 2016 to 2025. This chart illustrates how Shanghai Haohai Biological Technology Co. Ltd's total assets have evolved over time, based on quarterly financial data. See Shanghai Haohai Biological Technology Co (5HB) share price today for real-time trading data and today's change.
Shanghai Haohai Biological Technology Co. Ltd - Asset Composition Analysis
Shanghai Haohai Biological Technology Co. Ltd Total Assets Breakdown (December 2025)
Shanghai Haohai Biological Technology Co. Ltd total assets breakdown as of December 2025. Shanghai Haohai Biological Technology Co. Ltd's total assets of €6.72 Billion consist of 51.5% current assets and 48.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 36.4% |
| Accounts Receivable | €271.00 Million | 4.0% |
| Inventory | €522.88 Million | 7.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €539.73 Million | 8.0% |
| Goodwill | €271.10 Million | 4.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Shanghai Haohai Biological Technology Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Shanghai Haohai Biological Technology Co working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Haohai Biological Technology Co. Ltd's current assets represent 51.5% of total assets in 2025, a decrease from 67.4% in 2016.
- Cash Position: Cash and equivalents constituted 36.4% of total assets in 2025, down from 54.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, a decrease from 15.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 8.0% of total assets.
Shanghai Haohai Biological Technology Co. Ltd Competitors by Total Assets
Key competitors of Shanghai Haohai Biological Technology Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Shanghai Haohai Biological Technology Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.79 | 5.24 | 8.78 |
| Quick Ratio | 3.21 | 4.50 | 8.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €2.55 Billion | €3.03 Billion | €3.38 Billion |
Shanghai Haohai Biological Technology Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Shanghai Haohai Biological Technology Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.58 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -5.6% |
| Total Assets | €6.72 Billion |
| Market Capitalization | $73.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Haohai Biological Technology Co. Ltd's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shanghai Haohai Biological Technology Co. Ltd's assets decreased by 5.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai Haohai Biological Technology Co. Ltd (2016–2025)
The table below shows the annual total assets of Shanghai Haohai Biological Technology Co. Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €6.72 Billion ≈ $7.86 Billion |
-5.64% |
| 2024-12-31 | €7.12 Billion ≈ $8.33 Billion |
+0.22% |
| 2023-12-31 | €7.11 Billion ≈ $8.31 Billion |
+3.09% |
| 2022-12-31 | €6.89 Billion ≈ $8.06 Billion |
-0.83% |
| 2021-12-31 | €6.95 Billion ≈ $8.13 Billion |
+10.35% |
| 2020-12-31 | €6.30 Billion ≈ $7.36 Billion |
+2.39% |
| 2019-12-31 | €6.15 Billion ≈ $7.19 Billion |
+38.67% |
| 2018-12-31 | €4.44 Billion ≈ $5.19 Billion |
+8.86% |
| 2017-12-31 | €4.08 Billion ≈ $4.76 Billion |
+10.34% |
| 2016-12-31 | €3.69 Billion ≈ $4.32 Billion |
-- |
About Shanghai Haohai Biological Technology Co. Ltd
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally. The company offers ophthalmic implants, assistive devices, and medical devices; medical optical instruments, including intraocular lenses, endoscopic equipment, ophthalmic surgical instruments, and ot… Read more